ArticleJournal of biomolecular screening2015
Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4).
Article in Journal of biomolecular screening, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 31 citations in OpenAlex.
- Discovery of Pre-Clinical CandidateACS chemical neuroscience · 2025Article
- Genome-wide pan-GPCR cell libraries accelerate drug discovery.Acta pharmaceutica Sinica. B · 2024Review
- Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic MACS chemical neuroscience · 2024Article
- Discovery of VU6008677: A Structurally Distinct Tricyclic MACS medicinal chemistry letters · 2024Article
- Protocol for high throughput 3D drug screening of patient derived melanoma and renal cell carcinoma.SLAS discovery : advancing life sciences R & D · 2024Article
- Direct interrogation of context-dependent GPCR activity with a universal biosensor platform.Cell · 2024Article
- Direct interrogation of context-dependent GPCR activity with a universal biosensor platform.bioRxiv : the preprint server for biology · 2024Article
- Article
- Protocol for 3D screening of lung cancer spheroids using natural products.SLAS discovery : advancing life sciences R & D · 2023Article
- Lead identification using 3D models of pancreatic cancer.SLAS discovery : advancing life sciences R & D · 2022Article
- Discovery of structurally distinct tricyclic MBioorganic & medicinal chemistry letters · 2021Article
- Discovery and Optimization of Selective Inhibitors of Meprin α (Part I).Pharmaceuticals (Basel, Switzerland) · 2021Article
- Advances in G protein-coupled receptor high-throughput screening.Current opinion in biotechnology · 2020Review
- Rescue of mutant gonadotropin-releasing hormone receptor function independent of cognate receptor activity.Scientific reports · 2020Article
- Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening.SLAS discovery : advancing life sciences R & D · 2018Article
- Challenges in the development of an MBioorganic & medicinal chemistry letters · 2017Article
- Discovery of a novel 2,4-dimethylquinoline-6-carboxamide MBioorganic & medicinal chemistry letters · 2017Article
- Discovery of a novel, CNS penetrant MBioorganic & medicinal chemistry letters · 2017Article
- Challenges in the development of an MBioorganic & medicinal chemistry letters · 2017Article
- Optimization of MBioorganic & medicinal chemistry letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
Muscarinic acetylcholine receptors (mAChRs) have long been viewed as viable targets for novel therapeutic agents for the treatment of Alzheimer's disease and other disorders involving impaired cognitive function. In an attempt to identify orthosteric and allosteric modulators of the muscarinic acetylcholine receptor M(4) (M(4)), we developed a homogenous, multiparametric, 1536-well assay to measure M(4) receptor agonism, positive allosteric modulation (PAM), and antagonism in a single well. This assay yielded a Z' of 0.85 ± 0.05 in the agonist, 0.72 ± 0.07 in PAM, and 0.80 ± 0.06 in the antagonist mode. Parallel screening of the M(1) and M(5) subtypes using the same multiparametric assay format revealed chemotypes that demonstrate selectivity and/or promiscuity between assays and modalities. This identified 503 M(4) selective primary agonists, 1450 PAMs, and 2389 antagonist hits. Concentration-response analysis identified 25 selective agonists, 4 PAMs, and 41 antagonists. This demonstrates the advantages of this approach to rapidly identify selective receptor modulators while efficiently removing assay artifacts and undesirable compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.